Photo: Marcel Scholte / Unsplash
The OCCLUDE registry, now published in JVIR, reports complete target-vessel occlusion in 125 patients, though it had no comparison group and only a month of follow-up.
Background
Embolization, deliberately blocking a blood vessel from the inside, is a core tool of interventional radiology, used to stop bleeding and to starve tumors of their blood supply. Physicians have long had a menu of agents for the job, including metal coils, particles and gelatin sponge.
Obsidio Conformable Embolic, made by Boston Scientific, is a premixed gel of pre-hydrated gelatin and layered silicate, with tantalum powder added so it shows up on fluoroscopy [1]. It is delivered through a microcatheter and, according to the FDA clearance summary, conforms to the shape of the vessel "without relying on precipitation or polymerization" [1]. In short, it is a putty that knows where it is supposed to stop.
Obsidio is regulated through the FDA's 510(k) pathway; an earlier version was cleared on July 1, 2022 (K213385) [1]. A later clearance, issued October 3, 2024 (K242507), lists its indications as embolization of hypervascular tumors and of blood vessels to control bleeding or hemorrhage in the peripheral vasculature [1].
What Was Found
The OCCLUDE registry (NCT06170619) enrolled 125 patients consecutively at 19 U.S. hospitals, according to Boston Scientific [2,3]. Results were published in the Journal of Vascular and Interventional Radiology by Ketan Y. Shah, MD, and colleagues, and announced by the company on November 17 [3].
Patients ranged in age from 18 to 92, with a mean age of 59.1 years; 63.2% were men [2]. The most common health conditions were hypertension (54.4%), active cancer (36.0%) and diabetes (23.2%) [2]. The registry covered a wide range of anatomy: among 161 target lesions, the kidney's blood vessels were most common (25.5%), followed by musculoskeletal sites (19.3%), the inferior epigastric artery (9.9%), the upper gastrointestinal tract (9.3%), the liver (9.3%), the spleen (6.2%) and the lower gastrointestinal tract (2.5%) [2].
The company reports the following results [2,3]:
Occlusion: The primary effectiveness endpoint, target-vessel occlusion immediately after the procedure, was achieved in 100% of cases across 19 target-vessel types.
Rebleeding: No target-vessel rebleeding was reported through 30 days, and no target-vessel reintervention was needed.
Safety: Freedom from major adverse events through 30 days, the primary safety endpoint, was 97.4%, as reported by Endovascular Today from the company's announcement [3].
Combination use: Obsidio was used together with other embolics, including coils, particles or beads and gelatin sponge, in 38 vessels, or 23.6% [2,3].
That last figure deserves attention. Nearly a quarter of the time, operators reached for a second agent, which makes it harder to credit occlusion to Obsidio alone in those cases.
Study Design and Limitations
OCCLUDE was sponsored by Boston Scientific [3,4]. It is a prospective, post-approval, open-label, single-arm registry: every patient received Obsidio, and there was no comparison group treated with coils, particles or another agent [2,4]. That design can show how a device performs in routine practice, but it cannot show that the device is better than, or even equivalent to, the alternatives.
Follow-up for the reported endpoints ended at 30 days [2]. That is enough to capture early rebleeding and procedural complications, but not later recanalization, in which a blocked vessel reopens, or long-term outcomes for patients treated for tumors. Because patients with very different conditions were pooled, the 125-patient sample is spread thin across individual indications; results for any single use, such as splenic or gastrointestinal bleeding, rest on small numbers. Occlusion was also assessed by treating teams in an open-label setting.
VBN was unable to access the full JVIR paper or its abstract, so the authors' disclosures of financial relationships with Boston Scientific, and their own description of the study's limitations, could not be reviewed for this article. Results above are drawn from the company's registry summary and Endovascular Today's report of its announcement [2,3].
What Comes Next
For interventional radiologists, OCCLUDE offers multicenter, real-world data on a relatively new embolic across a broad mix of cases, with no rebleeding signal in the first month. The more useful next steps would be longer follow-up, indication-specific analyses and, ideally, comparative studies against established agents. Until then, the data show what Obsidio did in a sponsor-run registry, not how it stacks up against the coils already on the shelf.
This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.
References
U.S. Food and Drug Administration. 510(k) premarket notification K242507: Obsidio Conformable Embolic (Boston Scientific Corporation). Decision date October 3, 2024. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242507.pdf
Boston Scientific. Obsidio OCCLUDE registry. Boston Scientific (physician data page). Accessed November 19, 2026. https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology/obsidio-conformable-embolic/data/obsidio-occlude-registry.html
Endovascular Today. OCCLUDE registry data published for Boston Scientific's Obsidio conformable embolic. Endovascular Today. November 17, 2026. https://evtoday.com/news/occlude-registry-data-published-for-boston-scientifics-obsidio-conformable-embolic
ClinicalTrials.gov record NCT06170619, Obsidio Conformable Embolic Registry, as mirrored by Veeva Clinical Trials. Accessed November 19, 2026. https://ctv.veeva.com/study/a-prospective-post-approval-open-label-multi-center-united-states-us-registry-to-evaluate-the-e